Join Genetic Counselor and Assistant Professor at The Ohio State Wexner Medical Center, Jennifer Roggenbuck, on January 20th at 2:00 PM EST for a live webinar to learn more about genetic testing in ALS.
Trial News & Events
2015 NEALS Research Ambassador, Dexter Ang, was awarded the ALS Assistive Technology prize by The ALS Association and Prize4Life during this year's ALS/MND International Alliance Meeting.
Over 53 NEALS members authored posters presented at the 27th International Symposium on ALS/MND; 8 members chaired plenary sessions and 15 NEALS members presented platform presentations.
ALS Association Partnership to Fund RNS60 Treatment Trial with Biomarkers to Measure Neuroinflammati
The ALS Association, in partnership with ALS Finding a Cure and the Northeast ALS Consortium (NEALS), is pleased to announce $1 million in funding to support a new ALS clinical trial to test the efficacy of the experimental drug RNS60 in reducing inflammation that may hasten the disease process.
There have been a number of publications describing the important role of genetic counseling in amyotrophic lateral sclerosis (ALS). While such attempts at guiding who should undergo genetic testing are welcome, they are put forth in a vacuum because there are no data on where ALS neurologists stand in terms of genetic testing and counseling for the disease, and in terms of what is considered to be familial and sporadic ALS.
Research Ambassador, Mary Luper will share her experiences with ALS advocacy on November 14th at 3:00 PM EST. Register here.
NEALS co-chair Terry Heiman-Patterson will provide the keynote presentation at the 6th annual symposium on Nov. 7th in Chicago.
Join Dr. Merit Cudkowicz, Mass General Hospital, for a webinar on October 26th at 1:00 PM EDT to learn more aobut current and upcoming ALS clinical trials. Register here.
The 6th Annual ALS Clinical Research Learning Institute (CRLI), sponsored by The ALS Association, was held October 7 – 8, 2016 in Clearwater Beach, Florida. There were 37 people in attendance, including 11 patient-caregiver pairs, 4 returning research ambassadors and 7 faculty members.
Defining SOD1 ALS natural history to guide therapeutic clinical trial design. Read research paper here.